Description
Description
Retatrutide (40mg) is a high-concentration triple agonist peptide targeting GLP-1, GIP, and glucagon receptors. This research compound is utilized in advanced metabolic studies to evaluate dose-response relationships and the efficacy of triple receptor activation on energy expenditure and glycemic control.
Research Applications
Studies focus on the compound’s ability to modulate multiple metabolic pathways simultaneously, providing a comprehensive model for investigating complex endocrine interactions and potential therapeutic targets for metabolic resilience.
Reviews
There are no reviews yet.